Sham Feeding Post-operative Infants

Status Completed

Clinical Trial Summary

The purpose of this pilot study is to evaluate a feeding technique, sham feeding, to promote adequate oral skills in order to prevent oral aversion and/or poor oral skills due to the delay in oral feeds for surgical reasons. Sham feeding is intended for infants who are expected to have a prolonged course without normal enteral feeding by mouth.

Clinical Trial Description

There is a lack of literature and research on which to base interventions that intend to preserve and develop oral and motor feeding skills in the post-operative patient population during the critical window of opportunity to establish proper oral skills. Due to the lack of positive oral feeding stimuli (i.e. prolonged airway management, nasogastric tubes, and airway and upper GI suctioning), these patients are at risk to develop oral aversions that may negatively impact long-term outcomes.

Parents in the neonatal intensive care unit (NICU) report feelings of stress and loss of control associated with medical interventions. When normal oral feeding is contraindicated, there may be impairment of parent-child bonding and mothers may be less dedicated to providing milk for the infant. Impaired bonding has been shown to affect the parent-child relationship and the child's development long after discharge.

Sham feeding has been shown to be safe and shorten time to oral feeding in infants with esophageal atresia with delayed esophageal repair. Anecdotal evidence from Le Bonheur suggests that sham feeding in post-operative gastroschisis patients improves parental satisfaction and engagement.

There is no literature to describe the use of sham feeding in neonates other than those with esophageal atresia. Anecdotal reports from our institution and others institutions suggests that it increases parental engagement and improves parental satisfaction among patients with other bowel pathology.

This is a cohort study with historical controls within a single level IV NICU. Participants will be offered sham feeding by breast or bottle and observed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03350022
Study type	Interventional
Source	Le Bonheur Children's Hospital
Contact
Status	Completed
Phase	N/A
Start date	January 10, 2018
Completion date	September 4, 2019

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05635747` - A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
Completed	`NCT01891279` - Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?	N/A
Completed	`NCT00930644` - Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)	Phase 3
Completed	`NCT01696656` - Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency	N/A
Completed	`NCT00910104` - Cholestasis Reversal: Efficacy of IV Fish Oil	Phase 2/Phase 3
Completed	`NCT04981262` - Improved Quality of Life in Children With Intestinal Failure	N/A
Completed	`NCT01930539` - Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp	N/A
Recruiting	`NCT05023382` - A Study of Teduglutide in Japanese People With Short Bowel Syndrome
Recruiting	`NCT04733066` - Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis
Terminated	`NCT00742157` - Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)	Phase 4
Completed	`NCT04743960` - Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition	N/A
Completed	`NCT03690206` - Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)	Phase 3
Terminated	`NCT02266849` - Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study	Phase 3
Completed	`NCT01306838` - Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy	Early Phase 1
Completed	`NCT01380366` - rHGH and Intestinal Permeability in Intestinal Failure	Phase 4
Completed	`NCT00248573` - Mechanisms of Adaptation in Human Short Bowel Syndrome	Phase 1/Phase 2
Withdrawn	`NCT03371862` - Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)	Phase 2
Completed	`NCT04474743` - Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
Completed	`NCT00067860` - Diet/Growth Factor Mechanisms of Gut Adaptation	Phase 2
Terminated	`NCT04046328` - Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.